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NEUROPHARMACOLOGY OF COMPULSIVE EATING 
JULIA PANCIERA 
ABSTRACT 
 
 Compulsive eating behavior is a transdiagnostic construct observed in certain 
forms of obesity and eating disorders, as well as in the recently proposed ‘food 
addiction.’ Compulsive eating has been conceptualized as being comprised of three 
elements: i) habitual overeating, ii) overeating to relieve a negative emotional state, and 
iii) overeating despite adverse consequences. Neurobiological processes that include 
maladaptive habit formation, the emergence of a negative affect, and dysfunctions in 
inhibitory control are thought to drive the development and persistence of compulsive 
eating behavior. These complex psychobehavioral processes are under the control of 
various neuropharmacological systems. Here, we describe the current evidence 
implicating these systems in compulsive eating behavior, and contextualize them within 
the three elements. A better understanding of the neuropharmacological substrates of 
compulsive eating behavior has the potential to significantly advance the 
pharmacotherapy for feeding-related pathologies. 
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INTRODUCTION 
 
 Compulsivity is defined as a strong, irresistible internal drive to perform 
an action, typically contrary to one's will ("Compulsive", 2016). Within the context of 
feeding, compulsive eating behavior has been recognized as an underlying 
transdiagnostic construct of certain forms of obesity and eating disorders, as well as food 
addiction (Moore, Sabino, Koob, & Cottone, 2017). Obesity is rapidly surpassing 
common medical problems such as malnutrition and infectious diseases in prevalence 
(Organization, 2000). Indeed, the global prevalence of overweight and obesity is 
estimated to be 38%, with the United States and United Kingdom being among the 
countries with the fastest rate of increase (Ng et al., 2014). Obesity is defined as a body 
mass index (BMI) greater than 30 kg/ m2 (Organization, 2000), and it is often a 
consequence of recurrent overeating (Hill, Wyatt, Reed, & Peters, 2003). 
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Eating disorders affect an estimated 30 million adults in the US, with binge eating 
disorder (BED) having the highest lifetime prevalence at 2.0-3.5% for men and women, 
respectively (Hudson, Hiripi, Pope, & Kessler, 2007; Le Grange, Swanson, Crow, & 
Merikangas, 2012). BED is defined by abnormal and excessive eating behaviors in 
distinct rapid episodes, many including the intake of palatable food (American 
Psychiatric Association, 2013; Corwin & Buda-Levin, 2004). Food addiction is a recently 
proposed construct, whose prevalence rate is estimated at 5-15% (Gearhardt, Corbin, & 
Brownell, 2009; Pedram et al., 2013). Food addiction is diagnosed through the Yale Food 
Addiction Scale (YFAS), which utilizes criteria of Substance Use Disorders from the 
Diagnostic and Statistical Manual modified to reflect addictive behaviors towards food 
(American Psychiatric Association, 2013; Gearhardt et al., 2009; Gearhardt, Corbin, & 
Brownell, 2016). These disorders are highly comorbid as, for instance, 40-70% of 
individuals with BED are obese (Dingemans & van Furth, 2012; Kessler et al., 2013), and 
the incidence of food addiction is estimated to be approximately 25% in obese 
individuals (C. Davis et al., 2011; Pursey, Stanwell, Gearhardt, Collins, & Burrows, 
2014). Thus, it is of key importance to understand the neuropharmacological mechanisms 
that underlie the transdiagnostic construct of compulsive eating, in order to identify 
potential shared therapeutic targets.  
Three key, and not mutually exclusive, elements have been proposed to describe 
compulsive eating behavior: 1) habitual overeating, 2) overeating to relieve a negative 
emotional state, and 3) overeating despite adverse consequences (Moore et al., 2017). In 
this review, we seek to describe the current evidence implicating multiple 
	4 
neuropharmacological systems in the three elements of compulsive eating behavior. We 
will first briefly discuss the psychobehavioral processes and the neurocircuitry involved 
in each element. Next, we will specifically focus on individual neurotransmitter systems 
for which evidence of their contribution to one or more processes underlying the 
elements of compulsive eating exists. As the goal of this review is to compile the current 
state of knowledge of the neuropharmacology of compulsive eating specifically, a review 
of the systems involved in general eating behavior is beyond the scope (excellent reviews 
on this topic can be found elsewhere (Harrold, Dovey, Blundell, & Halford, 2012; Lutter 
& Nestler, 2009; Morton, Cummings, Baskin, Barsh, & Schwartz, 2006)). 
 
 
Psychobehavioral processes and neurocircuitry underlying the elements of 
compulsive eating behavior 
 
The three elements of compulsive eating behavior can be broadly mapped to 
dysfunctions of three key brain regions involving reward learning, emotional processing, 
and inhibitory control (Moore et al., 2017). The first element, habitual overeating, refers 
to the process by which a once goal-directed behavior becomes a maladaptive, stimulus-
driven habit (Belin & Everitt, 2008). The basal ganglia, the main sites of associative 
learning, include the ventral striatum (or nucleus accumbens, NAc), known for its role in 
reward and reinforcement, and the dorsal components of the striatum (e.g. dorsolateral 
striatum, DLS), which are considered the site of habit formation (Everitt & Robbins, 
2005). Similar to what has been hypothesized for drugs of abuse, chronic, repeated 
	5 
stimulations of dopaminergic system in the NAc by palatable food and associated cues 
shifts signaling to dorso-striatal dopaminergic pathways resulting in habit formation 
(Day, Roitman, Wightman, & Carelli, 2007; Everitt & Robbins, 2016; Stuber et al., 
2008). Therefore, compulsive eating is thought to reflect a maladaptive stimulus-driven 
habit, which overrides voluntary, goal-directed actions.  
The second element, overeating to relieve a negative emotional state, is defined 
as performing a behavior (intake of palatable food) in order to alleviate a negative 
emotional state (Koob, 2009; Koob & Volkow, 2010; Parylak, Koob, & Zorrilla, 2011). 
This element is embedded in the diagnostic criteria of compulsivity as observed in 
obsessive-compulsive disorder (OCD), where the repetitive behavior is preceded and 
driven by anxiety and distress, which are relieved after the behavior has been performed 
(Abramowitz & Jacoby, 2015). The neurobiological processes underlying this element 
are two-fold: within-system neuroadaptations producing functional desensitization of the 
mesocorticolimbic dopaminergic system, and between-system neuroadaptations which 
include the recruitment of the brain stress systems in the extended amygdala (Cottone, 
Sabino, Roberto, et al., 2009; Koob, 2015). Thus, a withdrawal-induced negative 
emotional state encompasses decreased reward, loss of motivation for ordinary rewards 
(Koob, 1996; Parylak et al., 2011), and increased anxiety (Cottone, Sabino, Roberto, et 
al., 2009; Koob, 1999). Accordingly, the transition to compulsive eating is hypothesized 
to result from the food acquiring negatively reinforcing properties (i.e. overeating 
alleviating a negative emotional state) (Cottone, Sabino, Roberto, et al., 2009; Iemolo et 
al., 2012; Koob & Le Moal, 2001; Parylak et al., 2011; Teegarden & Bale, 2007). 
	6 
The third element, overeating despite adverse consequences, describes the loss of 
control over food intake observed as a continuation of maladaptive overeating in the face 
of the resulting physical, psychological, and social negative consequences (Cottone et al., 
2012; Deroche-Gamonet, Belin, & Piazza, 2004; Hopf & Lesscher, 2014; Pelloux, 
Everitt, & Dickinson, 2007; Piazza & Deroche-Gamonet, 2013; Rossetti, Spena, Halfon, 
& Boutrel, 2014; Smith et al., 2015; Vanderschuren & Everitt, 2004; Velazquez-Sanchez 
et al., 2014). “Loss of control” is proposed to reflect deficits in inhibitory control 
mechanisms intended to suppress inappropriate actions. Inhibitory control processes are 
subserved by two main systems within the prefrontal cortex (PFC), conceptualized as a 
“GO” system (dorsolateral PFC [dlPFC], anterior cingulate [ACC], and orbitofrontal 
[OFC] cortices) and a “STOP” system (ventromedial PFC [vmPFC]). Hyperactivity of 
the “GO” system and hypoactivity of the “STOP” system are thought to underlie the loss 
of control characteristic of compulsive overeating despite consequences (George & 
Koob, 2013; Riga et al., 2014).  
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Table 1. A Summary of the Elements of Compulsive Eating Behavior and the 
Associated Features  
 
 
Elements of 
Compulsive 
Eating 
Behavior 
Neuropsychobiological 
Mechanisms 
Characteristic Behavior Most 
Implicated 
Brain 
Area 
Habitual 
Overeating 
Aberrant Reward 
Learning 
Inability to reduce eating or 
seeking behavior following a 
decrease in food value or 
contingency 
 
Basal 
Ganglia 
Overeating to 
Relieve a 
Negative 
Emotional 
State 
Affective Habituation  Eating to cope with decreased 
sensitivity to reward 
Basal 
Ganglia 
 Affective Withdrawal Eating to cope with negative 
affect 
(eg, anxiety and stress) 
 
Extended 
Amygdala 
Overeating 
Despite 
Negative 
Consequences 
Decreased Inhibitory 
Control 
Eating persists in conditions 
where it would normally be 
suppressed 
Prefrontal 
Cortices 
 
Reproduced with permission from (Moore, Sabino, Koob, & Cottone, 2017) 
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NEUROPHARMACOLOGICAL SYSTEMS UNDERLYING THE ELEMENTS 
OF COMPUSLIVE EATING BEHAVIOR  
 
Dopamine system 
 
The mesocorticolimbic dopaminergic pathway plays a major role in motivated 
behavior and its dysfunction is hypothesized to contribute to all three elements of 
compulsive eating: habitual overeating, overeating to relieve a negative emotional state, 
and overeating despite adverse consequences. In reinforcement learning, habit formation 
requires dopaminergic signaling in the anterior DLS (Yin & Knowlton, 2006). Dopamine 
type-1 receptor (D1R) neurons, which make up the direct, striatonigral pathway, drive 
enhanced dendritic excitability (Surmeier, Ding, Day, Wang, & Shen, 2007), and its 
relative dominance compared to dopamine type-2 receptor (D2R) signaling is one 
hypothesized mechanism of accelerated habit formation by drugs of abuse and palatable 
food (Furlong, Jayaweera, Balleine, & Corbit, 2014; Volkow, Wang, Tomasi, & Baler, 
2013b). Animals with a history of intermittent access to palatable food show habitual 
eating behavior, whereas chow-fed controls retain goal-directed food responding after 
devaluation (Furlong et al., 2014). In the DLS, animals that habitually overeat have 
increased c-fos activation in non-D2R containing neurons, suggesting that D1R neurons 
are activated in habitual eating (Furlong et al., 2014). Furthermore, injections of SCH-
23390, a D1R antagonist, into the DLS blocks the acquired habitual eating (Furlong et al., 
2014) and restores the sensitivity to devaluation in animals with a history of palatable 
food access.  
	9 
Over time, overstimulation of the mesocorticolimbic dopaminergic system from 
chronic exposure to highly-rewarding palatable food results in desensitization, which is 
hypothesized to contribute to the emergence of anhedonia and motivational deficits 
(Iemolo et al., 2012; Koob & Volkow, 2010). Compulsive eating would therefore emerge 
as a form of paradoxical self-medication to relieve these symptoms. There is evidence of 
downregulated dopamine signaling in obese individuals; availability of striatal D2Rs has 
indeed been found to be inversely correlated with BMI (Wang et al., 2001). Furthermore, 
the Taq1A polymorphism of the ankyrin repeat and kinase domain containing 1 
(ANKK1) downstream from the D2R gene (DRD2) was found to be correlated with 
decreases in D2R expression in the striatum (Eisenstein et al., 2016) and predisposition to 
obesity and substance use disorders (Noble, 2000; Stice, Spoor, Bohon, & Small, 2008). 
In obese individuals, blunted striatal responses to palatable food were found to be 
negatively correlated with BMI, an effect that was enhanced in those with the Taq1A 
allele (Stice et al., 2008). Similarly, rats bred to be obesity-prone displayed decreased 
reward system functioning, prior to (Valenza, Steardo, Cottone, & Sabino, 2015) and 
following the development of obesity (Johnson & Kenny, 2010). Following prolonged 
access to a high-fat diet, obese rats also exhibited compulsive eating behavior and 
decreased striatal D2Rs (Johnson & Kenny, 2010). Virally knocking down D2Rs within 
the striatum of rats prior to high-fat diet access worsened reward deficits and accelerated 
the emergence of compulsive eating behaviors (Johnson & Kenny, 2010), demonstrating 
a functional role of striatal D2Rs in compulsive eating. Thus, reduced striatal D2R 
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density and compromised dopamine signaling may cause overeating to compensate for 
such reward deficit.  
Vulnerabilities or neuroadaptations of prefronto-cortical dopaminergic signaling 
are thought to underlie the loss of control that leads to continued intake despite negative 
consequences (Tomasi & Volkow, 2013; Volkow & Fowler, 2000; Volkow, Wang, 
Tomasi, & Baler, 2013a). Within the PFC, specifically in the OFC and the ACC, the 
decreased dopamine activity seen in addiction and obesity is associated with decreased 
inhibitory control (Volkow & Wise, 2005). Lower striatal D2Rs, a consequence of 
obesity or the Taq1a polymorphism, is also associated with corresponding deficits in 
prefrontal activity (Noble, Gottschalk, Fallon, Ritchie, & Wu, 1997; Volkow et al., 2008). 
In humans with BED, having a Val(108/158)Met polymorphism in the gene for catechol-
methyl-transferase (COMT) is associated with greater inhibitory control deficits (Leehr et 
al., 2016). COMT is an enzyme that catalyses the degradation of dopamine, which is 
particularly important in the PFC, as a lower expression of the dopamine transporter is 
observed in this area (Chen et al., 2004). This polymorphism is characterized by a 
substitution of Met (low enzymatic activity) for Val (high enzymatic activity), governing 
more rapid dopamine degradation and blunted prefrontal dopaminergic transmission 
(Chen et al., 2004).  
Lisdexamfetamine (LDX), the only pharmaceutical drug currently approved for 
treatment of BED (Administration, 2015), works through modulation of monoamine 
transmission, including dopamine. LDX is a prodrug of d-Amphetamine: elevating 
extracellular monoamine levels through inhibition of membrane and vesicular 
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monoamine transporters (Freyberg et al., 2016; Rowley et al., 2012). Treatment with 
LDX has been shown to directly decrease compulsive eating in rats (Heal, Goddard, 
Brammer, Hutson, & Vickers, 2016) as well as humans, as measured by the Yale-Brown 
obsessive compulsive scale modified for binge eating (Y-BOCS-BE) (McElroy et al., 
2016). LDX likely exerts therapeutic effects on both the second and third elements of 
compulsive eating through restoration of deficient dopaminergic transmission in the basal 
ganglia as well as prefrontal areas. LDX administration produces sustained increases in 
striatal dopamine in rats (Rowley et al., 2012), which could recover low dopaminergic 
states characteristic of compulsive overeating to relieve a negative emotional state. 
Additionally, likely by increasing extracellular concentrations of dopamine in the PFC 
(Heal, Cheetham, & Smith, 2009; Rowley et al., 2012), LDX improved dysfunctions in 
inhibitory control in humans with BED (McElroy et al., 2016) that are associated with 
overeating despite consequences. Thus, by increasing extracellular dopamine levels, LDX 
may effectively restore dopaminergic dysfunctions associated with multiple elements of 
compulsive eating behavior. 
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Opioid system 
 
All three elements of compulsive eating behavior are likely influenced by the 
opioid system. Of the opioid receptor subtypes, the mu- and the kappa-opioid receptors 
have been implicated in compulsive eating behavior in varying degrees. The mu-opioid 
system has been known traditionally for its role in hedonic feeding, even though more 
recently it has gained attention also as a regulator of incentive motivation for food 
rewards and associated cues (Giuliano & Cottone, 2015; Laurent, Morse, & Balleine, 
2015; Wassum, Cely, Maidment, & Balleine, 2009), key contributors to changes in 
action-outcome vs. stimulus-driven, habitual overeating (Corbit, 2016). In humans with 
BED, the selective mu-opioid receptor antagonist GSK1521498 decreased consumption 
of palatable food as well as attentional bias to palatable food cues (Chamberlain et al., 
2012; de Zwaan & Mitchell, 1992). Naltrexone, a mixed opioid receptor antagonist, 
decreased neural responses to food cues in healthy subjects, as shown by a reduced 
activation of the ACC and the dorsal striatum (Murray et al., 2014). A “gain of function” 
polymorphism of the mu-opioid receptor gene (OPRM1) was found to be associated with 
BED (C. A. Davis et al., 2009) and hypothesized to cause hyperreactivity to the hedonic 
properties of food and predisposition to binge eating (C. A. Davis et al., 2009).  
Changes in mu- opioid receptor systems also occur during withdrawal from 
palatable food, and they may play a role in the emergence of the negative emotional state 
that drives compulsive eating behavior. Rats given intermittent sucrose access show 
upregulated mu-opioid receptor binding and downregulated enkephalin mRNA in the 
NAc, which is interpreted to reflect a compensatory mechanism following prolonged 
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endogenous opioid release following palatable food (Hoebel, Avena, Bocarsly, & Rada, 
2009). Consequently, a withdrawal state can be precipitated in these rats through 
administration of the mu-opioid antagonist, naloxone, resulting in somatic signs and 
anxiety-like behavior (Colantuoni et al., 2002). Naloxone treatment was also shown to 
cause a drop in extracellular dopamine (-18-27%) and increased acetylcholine release 
(+15-34%) in sucrose-withdrawn rats relative to chow-fed controls (Colantuoni et al., 
2002).  
There is also evidence for both mu- and kappa- opioid system dysfunction in the 
PFC in compulsive eating, hypothesized to underlie deficits in inhibitory control 
processes underlying overeating despite negative consequences. Mu-opioid receptor 
stimulation in the vmPFC was shown to both promote feeding (Mena, Sadeghian, & 
Baldo, 2011a) and induce deficits in inhibitory control (Selleck et al., 2015), which 
resulted from increased motivational food value and disinhibited behavioral output 
(Selleck & Baldo, 2017). Furthermore, within the medial PFC (mPFC), administration of 
naltrexone dose-dependently and selectively reduced consumption of, and motivation for, 
palatable food in an animal model of compulsive eating (Blasio, Steardo, Sabino, & 
Cottone, 2014; Cottone et al., 2012). Conversely, naltrexone microinfusion into the NAc 
non-selectively suppressed chow and palatable food intake and motivation for food 
(Blasio, Steardo, et al., 2014), demonstrating a selectivity of manipulations to prefrontal 
opioid signaling (vs. striatal) on binge-eating of palatable food. Furthermore, animals 
with intermittent access to a palatable diet displayed increased expression of the gene 
coding for the opioid peptide pro-dynorphin (PDyn) and reduced expression of the pro-
	14 
enkephalin (PEnk) gene in the mPFC. These results suggest that neuroadaptations to the 
prefrontal opioid system contribute to maladaptive food intake, likely through 
dysfunction of inhibitory control processes (Mena, Sadeghian, & Baldo, 2011b).  
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Corticotropin-Releasing Factor (CRF)-CRF1 receptor system 
 
There is compelling evidence that the extra-hypothalamic corticotropin-releasing 
factor (CRF)-CRF1 receptor system is a driving factor of compulsive overeating to 
relieve a negative emotional state (Cottone, Sabino, Roberto, et al., 2009; Iemolo et al., 
2013). Chronic, intermittent cycles of palatable food exposure and withdrawal are 
hypothesized to progressively recruit the CRF-CRF1 receptor system (Cottone, Sabino, 
Roberto, et al., 2009), observed as an increase in CRF in the central nucleus of the 
amygdala (CeA) of animals during withdrawal from palatable food (Cottone, Sabino, 
Roberto, et al., 2009; Zorrilla, Logrip, & Koob, 2014). Up-regulation of CRF-CRF1 
system is hypothesized to ultimately produce the negative emotional state observed in 
withdrawal referred to as the “dark side” of addiction (Cottone, Sabino, Roberto, et al., 
2009; Iemolo et al., 2013; Koob, 2008). Rats with a history of intermittent palatable food 
displayed anxiety- and depressive-like behaviors when the palatable food was no longer 
available (i.e. withdrawal) (Cottone, Sabino, Roberto, et al., 2009; Cottone, Sabino, 
Steardo, & Zorrilla, 2008, 2009; Iemolo et al., 2012). Renewed access then resulted in 
overconsumption of palatable food and a complete alleviation of the negative emotional 
state (Iemolo et al., 2012). Accordingly, administration of the selective CRF1 receptor 
antagonist R121919 into the CeA blocked both withdrawal-induced anxiety-like behavior 
and compulsive eating of palatable food when access to the palatable diet was restored 
(Cottone, Sabino, Roberto, et al., 2009; Iemolo et al., 2013).  
The CRF-CRF1 system in the bed nucleus of the stria terminals (BNST) may also 
underlie binge eating that is precipitated by stress (Micioni Di Bonaventura et al., 2014). 
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The BNST is involved in the stress response, and is activated by intermittent access to 
palatable food in an animal model that also uses cycles of stress (Micioni Di Bonaventura 
et al., 2014). R121919 infusion into the BNST was able to block stress-induced binge 
eating in this model (Micioni Di Bonaventura et al., 2014). In a different animal model of 
genetic susceptibility to stress-induced binge eating, stress increased brain expression of 
CRF mRNA in the BNST of binge-eating prone, but not binge eating resistant rats 
(Calvez, de Avila, Guevremont, & Timofeeva, 2016). Thus, CRF in the BNST may 
modulate compulsive eating driven by stressful conditions and may interplay with the 
CeA to cause negative emotional states.  
Guided by promising evidence in animal models, in 2016, a randomized, double-
blinded, placebo-controlled study analysed the effects of the CRF1 antagonist 
pexacerfont on stress-induced eating in healthy adult “restrained eaters.” Although this 
study was terminated early for reasons unrelated to any adverse effects of pexacerfont, 
researchers found promising results in reductions in ratings of food 
problems/preoccupations using the YFAS, as well as reductions in food craving and 
eating, though independent of stress condition (Epstein et al., 2016). Even with reduced 
sample size, this clinical trial demonstrated a strong positive potential of CRF1 
antagonists in reducing food cravings in chronic dieters (Epstein et al., 2016). CRF1 
antagonists are proposed to be most effective in certain psychiatric disorders specifically 
demonstrating CRF overactivation; thus, future clinical trials evaluating efficacy of CRF1 
antagonists specific to certain disorders, circumstances, or patient subgroups have been 
called for (Koob & Zorrilla, 2012; Spierling & Zorrilla, 2017). 
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Cannabinoid receptor 1 (CB1) system 
 
The cannabinoid type 1 (CB1) receptor system within the amygdala modulates the 
negative emotional state associated with compulsive eating. In drug addiction, repeated 
cycles of intoxication and withdrawal result in the recruitment of the endocannabinoid 
system within amygdalar circuits, which is hypothesized to act as a “buffer system” to 
CRF-CRF1 receptor system over-activation (Hillard, Weinlander, & Stuhr, 2012; Koob, 
2015; Koob et al., 2014; Patel, Cravatt, & Hillard, 2005; Sidhpura & Parsons, 2011). 
Similarly, during withdrawal from palatable food, the endocannabinoid 2-
arachidonoylglycerol (2-AG) and CB1 receptor expression were found to be increased in 
the CeA (Blasio et al., 2013). Systemic and CeA site-specific infusion of the CB1 
receptor inverse agonist rimonabant precipitated anxiety-like behavior and anorexia of 
the standard chow diet during withdrawal from palatable food (Blasio et al., 2013; Blasio, 
Rice, Sabino, & Cottone, 2014). Importantly, rimonabant did not increase anxiety-like 
behavior in chow-fed control animals (Blasio et al., 2013; Blasio, Rice, et al., 2014). 
Therefore, the endocannabinoid system of the amygdala is hypothesized to be recruited 
during withdrawal from palatable food as a compensatory mechanism to dampen anxiety. 
Thus, endocannabinoids may help buffer the negative emotional state associated with 
withdrawal from food, and rimonabant may precipitate a withdrawal-like syndrome in a 
subpopulation of obese individuals abstaining from palatable food as they attempt to lose 
weight (e.g. by dieting). This mechanism may therefore explain the emergence of severe 
psychiatric side-effects following rimonabant treatment in obese patients (Christensen, 
Kristensen, Bartels, Bliddal, & Astrup, 2007).  
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The CB1 system also contributes to overeating despite negative consequences. In 
rats with a history of intermittent access to palatable food, rimonabant decreased 
palatable food intake to a greater extent than in chow-fed controls and also blocked 
compulsive eating of palatable food in a light/dark conflict test (Dore et al., 2014). While 
the exact site of action mediating this effect is unknown, following intermittent access to 
a high-sucrose, palatable diet, animals had upregulated CB1 receptor gene expression in 
the dorsal striatum (Dore et al., 2014), suggesting that increased expression of CB1 
receptors in diet-cycled rats may work by modulating dopamine release (Dore et al., 
2014; Szabo, Muller, & Koch, 1999).  
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Glutamatergic system 
 
Two major classes of glutamatergic receptors (a-amino-3-hyrdixy-5-methyl-
4isoxazolepropionic acid [AMPA], and N-methyl-D aspartate [NMDA] receptors) have 
been found to be involved in to compulsive eating behaviors, specifically habitual 
overeating as well as overeating despite aversive consequences. Habitual intake of 
palatable food is dependent on AMPARs in the DLS, one of the main brain areas 
involved in habit formation. Infusion of the AMPA/kainate receptor antagonist, CNQX 
(6-cyano-7-nitroquinoxaline-2,3-dione) into the DLS blocked habitual intake, restoring 
sensitivity to devaluation of the palatable food (Furlong et al., 2014). 
NMDARs are hypothesized to be associated with the element of overeating 
despite adverse consequences via an interaction with inhibitory control processes. 
Memantine, an NMDAR uncompetitive antagonist, reduced binge eating and 
“disinhibition” of eating behaviors in an open-label, prospective trial with humans 
(Brennan et al., 2008). Memantine has also been shown to reduce impulsivity and 
enhanced cognitive control in compulsive shoppers (Grant, Odlaug, Mooney, O'Brien, & 
Kim, 2012), a proposed behavioral addiction with similarities to compulsive eating. In 
compulsive eating animals exposed to daily intermittent access to a palatable diet, 
microinfusion of memantine into the NAc shell reduced binge-like eating (Smith et al., 
2015), indicating that the NMDAR system in the NAc shell is recruited in compulsive 
eating rats. Activity within the NAc is modulated by glutamatergic projections 
originating from the PFC (Brog, Salyapongse, Deutch, & Zahm, 1993; McGeorge & 
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Faull, 1989; Zahm & Brog, 1992). Memantine also blocked food-seeking and compulsive 
eating of palatable food (Smith et al., 2015).  
Within the NAc core, high fat diet induced obesity caused alterations in 
glutamatergic synaptic plasticity, including increased potentiation at glutamatergic 
synapses, loss in ability of these potentiated synapses to undergo long-term depression 
(LTD) and slower NMDA-mediated currents (Brown et al., 2015). Synaptic impairments 
were associated with food addictive-like behavior, including increased motivation, 
excessive intake, and increased food seeking when the food was not available (Brown et 
al., 2015). Dysregulated signaling at cortico-accumbens synapses are hypothesized to 
impair normal accumbal processing of motivation information and inhibition of 
responding (Gipson, Kupchik, & Kalivas, 2014), likely resulting in loss of control over 
intake and overeating despite consequences.  
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Sigma-1 receptor (Sig-1R) system 
 
Sigma-1 receptors (Sig-1Rs) play a major role in the pathophysiology of addictive 
disorders encompassing multiple drugs of abuse, and have also been shown to modulate 
compulsive overeating despite adverse consequences (Cottone et al., 2012; Sabino & 
Cottone, 2016; Sabino, Hicks, & Cottone, 2017; Valenza, DiLeo, Steardo, Cottone, & 
Sabino, 2016). In animals with daily, intermittent access to palatable food, systemic 
treatment with the Sig-1R antagonist BD-1063 selectively decreased palatable food 
intake in a dose-dependent manner (Cottone et al., 2012). Additionally, in the same study, 
BD-1063 blocked compulsive eating behavior in face of adverse conditions (Cottone et 
al., 2012). Bingeing, compulsive eating rats showed a two-fold increase in Sig-1R protein 
levels in the ACC (Cottone et al., 2012). Thus, prefrontal Sig-1R system may play a role 
in compulsive eating (Cottone et al., 2012), perhaps due to neuromodulation of dopamine 
and glutamate signaling (Bastianetto, Rouquier, Perrault, & Sanger, 1995; Dong et al., 
2007). 
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Cholinergic system 
 
Imbalance in Acetylcholine (ACh) signaling in the NAc is characteristic of 
withdrawal from drugs of abuse (Rada, Mark, Taylor, & Hoebel, 1996), and has also 
been observed during withdrawal from palatable food (Colantuoni et al., 2002), 
implicating this system as a key player in the associated negative emotional state. 
Similarly, in rats with alternating access to sucrose solution and chow food, followed by 
12h with no food access to induce bingeing, both spontaneous and naloxone-precipitated 
withdrawal caused an increase in extracellular ACh in the NAc (Avena, Bocarsly, Rada, 
Kim, & Hoebel, 2008; Colantuoni et al., 2002). This increased ACh was also 
accompanied by decreased dopaminergic signaling, as well as somatic withdrawal signs 
and anxiety-like behavior (Colantuoni et al., 2002). Within the NAc, the functional 
interaction between dopaminergic and cholinergic systems has a critical effect on the 
motivation to eat (Hernandez & Hoebel, 1988; Hoebel, Avena, & Rada, 2007), in that 
hungry rats stopped feeding if the balance between the two shifted towards cholinergic 
tone (Mark, Shabani, Dobbs, & Hansen, 2011). Elevated levels of ACh in the NAc also 
result in aversion during low dopamine states (Aartsen et al., 2016; Hoebel et al., 2007), 
and may therefore contribute to aversive state of withdrawal.  
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Trace Amine-Associated Receptor-1 (TAAR1) system 
 
Recent evidence suggests the Trace Amine-Associated Receptor-1 (TAAR1) 
system participates in compulsive overeating despite adverse consequences, likely 
through the involvement of PFC circuits. TAAR1 is a G-protein coupled receptor 
activated by trace amines as well as other neurotransmitters such as dopamine and 
serotonin (Borowsky et al., 2001). The TAAR1 system has recently come under attention 
for evidence of its role in regulating the behavioral actions of psychostimulants 
(Harkness, Shi, Janowsky, & Phillips, 2015; Liu, Thorn, Zhang, & Li, 2016; Pei, Mortas, 
Hoener, & Canales, 2015; Sukhanov et al., 2016; Thorn et al., 2014; Wolinsky et al., 
2007) but also impulsive-like behavior (Espinoza et al., 2015). A recent study (2016) 
explored the role of the TAAR1 system in binge and compulsive eating in rats following 
daily, intermittent access to palatable food. Systemic injections of the selective TAAR1 
agonist RO5256390 fully and selectively blocked binge eating of palatable food, the 
expression of conditioned place preference for palatable food, as well as compulsive-like 
eating in a light/dark conflict test (Ferragud et al., 2016). Furthermore, binge-eating 
animals had decreased protein expression of TAAR1 receptors in the PFC (Ferragud et 
al., 2016). Injections of RO5256390 site specifically into the infralimbic, but not 
prelimbic, cortex recapitulated the blockade of bingeing in compulsive eating rats 
(Ferragud et al., 2016). These results suggest that TAAR1 may have an inhibitory role 
over feeding behavior, and that loss of this function may be responsible for compulsive 
binge eating. Interestingly, TAAR1s are also activated by amphetamine (Borowsky et al., 
2001), the active metabolite in the BED therapeutic LDX (Goodman, 2010). LDX and 
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TAAR1 agonism may, therefore, work through similar mechanisms to restore impaired 
prefrontal control over inhibitory behaviors. 
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Serotonin system 
 
Serotonin (5-hydroxytrptamine, 5-HT) neurotransmission has been extensively 
studied in feeding and eating disorders, including BED (Jimerson, Lesem, Kaye, & 
Brewerton, 1992), and has been linked to compulsive behaviors in OCD and bulimia 
nervosa (Fineberg, Roberts, Montgomery, & Cowen, 1997; Steiger, Israel, Gauvin, Ng 
Ying Kin, & Young, 2003). Patients with BED show reduced 5-HT release in the 
hypothalamus, lower 5-HT transporter binding in the midbrain, and higher 5-HT2a and 5-
HT5 binding in the NAc shell (De Fanti, Gavel, Hamilton, & Horwitz, 2000; Kuikka et 
al., 2001; Ratner et al., 2012). Serotonergic drugs, such as selective serotonin reuptake 
inhibitors (SSRIs), have been studied as potential therapeutics for BED (McElroy, 
Guerdjikova, Mori, & Keck, 2015; Milano et al., 2005). There is a known role for the 
serotonin system in anxiety and depressive disorders; and lower 5-HT activity was found 
to predict negative mood prior to binge eating (Steiger et al., 2005). d-Amphetamine, 
which inhibits monoamine reuptake, including serotonin, has been shown to increase 5-
HT concentrations in the striatum ((Hernandez, Lee, & Hoebel, 1987)). Thus, LDX may 
also restore serotonergic activity contributing to its ability to reduce compulsive eating 
behavior.  
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DISCUSSION 
 
 The pathology underlying compulsive eating behaviors involves 
neuroadaptations in a variety of neurotransmitter and neuropeptide systems. There is 
much left to understand about the complexity of these behaviors and associated disorders, 
as well as disease process. The construct of compulsive eating has only recently gained 
attention; thus, it is likely that many additional systems have yet to be identified as 
having a direct role in compulsive eating. Examples include the noradrenergic system, 
gamma-aminobutyric acid (GABAergic), glucagon-like peptide 1 systems, and oxytocin 
systems; each known to modulate reward, feeding, and/or addiction to drugs of abuse 
(Egecioglu et al., 2013; Latagliata, Patrono, Puglisi-Allegra, & Ventura, 2010; Lee, Jang, 
& Noh, 2016; Nieh et al., 2015).  
Variations in genes that regulate the reward and anti-reward systems may result in 
susceptible phenotypes, and innate, individual differences may contribute to the 
development of maladaptive eating behaviors. As discussed above, polymorphisms in 
genes such as OPRM1 and ANKK1/DRD2 have been linked to decreased reward and a 
susceptibility to obesity, as well as substance use disorders (C. Davis, 2015). Other 
polymorphisms, such as to the COMT gene, which is associated with prefrontal 
modulation of the inhibitory control, have also been liked to binge eating in humans 
(Leehr et al., 2016). Only recently, discovery-based genetic approaches in animal models 
are being used to uncover novel genetic and biological mechanisms of eating disorders; 
for instance, the gene for cytoplasmic- FMR1-interacting protein 2 was associated with 
binge and compulsive eating (Kirkpatrick et al., 2016). Some animal models use an 
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individual differences approach (e.g. binge eating prone vs. resistant in response to a 
stressful stimuli), which may generate innovative hypotheses regarding vulnerabilities to 
develop compulsive eating behavior (Boggiano et al., 2007). Further genetic and 
epigenetic studies in animal models of compulsive eating have the potential to point to 
neurotransmitter and neuropeptide systems that regulate vulnerability to eating disorders 
and obesity. 
Additionally, exposure and schedule of access to highly palatable food cause 
neuroadaptations that alter the functioning of these systems. Highly controlled, 
preclinical studies have led to discovery of the involvement in the CRF-1, CB1, Sigma-1 
systems, and others. To this end, animal models have contributed to the growing 
literature on disturbances in neurobiology causing compulsive eating. Therefore, there is 
a strong need for modelling complex cognitive behaviors in order to produce clinically 
relevant animal studies. For example, certain neurotransmitter and neuropeptide systems 
which are involved in reward, motivation, and some aspects of hedonic eating may, 
however, exert no influence over compulsive eating. Thus, adopting strategies to model 
compulsivity in addition to or in lieu of rewarding properties alone are more likely to 
yield translational treatment approaches. 
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CONCLUSION 
 
As described above, compulsive eating behavior is a transdiagnostic component 
of obesity, other eating disorders, and the recently proposed construct of food addiction. 
The behaviors that make up compulsivity are driven by three underlying elements: 1) 
habitual overeating, 2) overeating to relieve a negative emotional state, and 3) 
overeating despite adverse consequences (Moore, Sabino, Koob, & Cottone, 2017). The 
elements of compulsive behaviors are the product of several neuroadaptations to areas 
such as the basal ganglia, the amygdala, and the prefrontal cortex.  
This review discussed some of the neurotransmitter and neuropeptide systems that 
influence the elements of compulsive eating. Although not mentioned in this review, 
there are several other aspects to this disease that influence the development of obesity in 
individuals, including metabolic disorders and the homeostatic influence on the hedonic 
mechanisms. 
Compulsive eating behaviors are proposed to contribute to some forms of obesity, 
as well as other disorders such as BED and food addiction. This is hypothesized to be 
attributed to the disruption of normal psychobehavioral processes influencing compulsive 
intake of palatable foods.  
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